Acadia Pharmaceuticals | ACAD - Sales Revenues


Acadia Pharmaceuticals reported $278.6M in Sales Revenues for its fiscal quarter ending in September of 2025.





Sales Change Date
Acadia Pharmaceuticals USD 278.6M 14M Sep/2025
ALKERMES USD 394.2M 3.5M Sep/2025
Alnylam Pharmaceuticals USD 1.25B 476.31M Sep/2025
Biogen USD 2.53B 70M Sep/2025
BioMarin Pharmaceutical USD 776M 49M Sep/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Corcept Therapeutics USD 207.6M 13.2M Sep/2025
Cytokinetics USD 1.93M 64.83M Sep/2025
Eisai JPY 197.36B 5.29B Sep/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
Incyte USD 1.37B 310M Sep/2025
J&J USD 24.6B 610M Dec/2025
Moderna USD 1.02B 878M Sep/2025
Neurocrine Biosciences USD 794.9M 107.4M Sep/2025
Pfizer USD 17.58B 880M Dec/2025
Prothena USD 2.42M 2M Sep/2025
PTC Therapeutics USD 211M 32.1M Sep/2025
Sarepta Therapeutics USD 399.4M 211.69M Sep/2025
Ultragenyx Pharmaceutical USD 160M 6.5M Sep/2025
Vertex Pharmaceuticals USD 3.08B 120M Sep/2025